Clinical trialPhase 1 / Phase 2Terminated
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumour Activity of the MYC Inhibitor OMO-103 Administered Intravenously in Patients With Advanced Solid Tumours
- Outcome
- Stopped early. Results posted; single-arm, no comparisonPhase 1completed; sponsor decided to change strategy to a combination study (Business decision)
- Phase
- Phase 1 / Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 28 April 2021
- Ended
- 11 January 2023
- Enrollment
- 22 participants
- Sites
- 3
- Primary outcomes
- Phase 1: Safety and Tolerability
- Sponsor type
- Industry
- Results posted
- 25 April 2024
- Last update
- 25 April 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 25 April 2024
- Primary outcome
- Phase 1: Safety and TolerabilityDLT DLT: OMO-103: 1, n = 22TEAEs: OMO-103: 18, n = 22SAEs: OMO-103: 9, n = 22IRRs: OMO-103: 10, n = 22Values: participantsTime frame: DLT period was 3 weeks and AEs were assessed for each patient until progression which was in average 3 months;No analysis posted for this outcome (outcome 1)
- Participants
- OMO-103: 22 started, 22 completed
- Serious adverse events
- OMO-103: 9 of 22Participants with at least one serious adverse event, of those at risk, as posted
1 secondary outcome
- Phase 1: Elimination Half Life (t1/2)
- OMO-103 38 (19), n=22 [mean hours, Standard Deviation]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is an open label, two-part, First in Human (FIH) Phase 1/2 dose-finding study designed to determine the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and proof-of-concept (POC) of OMO-103 in patients with advanced solid tumours.
Detailed description public domain (ClinicalTrials.gov)
This study is an open label, two-part, FIH Phase 1/2 dose-finding study designed to determine the safety, tolerability, PK, PD and proof-of-concept of OMO-103 in patients with advanced solid tumours. The study consists of two parts: • Part 1: Dose escalation in patients with advanced solid tumours, including 5 OMO-103 dose levels. Approximately 11 to 24 patients in total will be enrolled in Part 1, covering 5 dose levels with the primary objective of determining the safety and tolerability of OMO-103 and defining an appropriate dose for further evaluation in Part 2. The study will start with an accelerated-titration dose-escalation scheme enrolling one evaluable patient per cohort for the first 2 dose levels followed by a classic 3+3 design. • Part 2: Dose expansion where at least 3 parallel groups of patients with advanced Non Small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC) and Colorectal Cancer (CRC) will be treated at the recommended Phase 2 dose (RP2D) of OMO-103 to further characterise the safety, tolerability, PK, PD and anti-tumour activity of OMO-103. Approximately 18 patients will be enrolled in each of the 3 parallel groups of patients (NSCLC, TNBC, CRC) in Part 2.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Phase 1: Safety and Tolerability [DLT period was 3 weeks and AEs were assessed for each patient until progression which was in average 3 months;]. Number, participants. DLT DLT: OMO-103 (n=22): 1. TEAEs: OMO-103 (n=22): 18. SAEs: OMO-103 (n=22): 9. IRRs: OMO-103 (n=22): 10.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Phase 1: Elimination Half Life (t1/2) [0, 5, 30, 60 min, 1, 2, 6, 24, 48, 76, 94 hours after end of infusion]. Mean, hours (Standard Deviation). OMO-103 (n=22): 38 (19).